Add impact to your LinkedIn
Keep up with the latest updates, insights, and opportunities driving meaningful change in the healthcare industries
Follow us
ARCHIMED earns 5x its investment, selling a majority of Ad-Tech to Tokyo-listed Nihon Kohden
learn more >10,500+
people employed
by ARCHIMED companies.
ARCHIMED is focused on accelerating the development of healthcare industries and solutions to the benefit of people and patients around the world.
About us
+15%
average annual topline growth
of ARCHIMED companies.
We fund, support and scale companies whose activities contribute to improve health outcomes at all levels.
Our companies
WATCH MORE VIDEOS
ARCHIMED funds healthcare industries globally.
Fund
Read more
ARCHIMED funds healthcare entrepreneurs’ ambitions while the EURÊKA Foundation funds charitable research programs on unmet medical needs.
€10M to 1B
investment size.
Through its discretionary funds, ARCHIMED invests between 10 million and 1 billion euros in leading companies.
€8B
managed assets.
ARCHIMED’s currently managed assets represent eight billion euros.
>400
sub-sectors.
ARCHIMED’s MedSeg is split into more than 400 sub-sectors, individually assessed by sector and Impact teams, and consequently prioritized in terms of investment focus.
Our Latest Investment
SeqCenter is a leading service provider of a recently developed technology, Next-Generation Sequencing (NGS) that’s used for mapping the DNA and RNA information that cells use to develop and operate. NGS sequences genes more rapidly, with greater reliability and at lower cost than traditional techniques.
ARCHIMED’s team supports healthcare entrepreneurs to accelerate their company’s development.
support
Read more
ARCHIMED’s team supports the business development efforts of healthcare companies as well as helping vulnerable people to return to social and professional life.
+15%
average annual topline growth
of ARCHIMED companies.
60%
growth rate.
ARCHIMED is accelerating companies growth rate by more than 60% compared to pre-ARCHIMED performance.
7
healthcare sectors.
ARCHIMED invests globally across 7 prioritized healthcare sectors.
Our Latest Exit
Founded in Greater Milwaukee in 1983, Ad-Tech is the world’s leading manufacturer of intracranial neuro electrodes. Ad-Tech’s minimally invasive devices provide brain mapping used in the diagnostics and treatment of a wide range of disorders, including epilepsy. Ad-Tech products are approved for use in more than 60 countries and have a strong reputation among the neurosurgical community.
ARCHIMED delivers superior returns to investors, and to society through the EURÊKA Foundation.
ARCHIMED provides superior returns to investors, allowing people a better life through their pensions and with more fruitful savings – 5% of ARCHIMED’s profit from carried interest is returned to the community through EURÊKA, ARCHIMED’s charitable foundation.
10%
Top decile performers.
ARCHIMED’s first three funds MED I (2014), MED II (2018) and MED Platform I (2019) are at least top decile performers.
100%
All ARCHIMED team members
benefit from carried interest (fund-based long-term incentive plan).
Art. 9
Funds
that have sustainable investment as their objective.
Our Latest Project
The EURÊKA Foundation actively supports the global development of Clubhouse, an operator of non-medicalized day houses for the support of people with severe mental issues.
